AlzeCure to present promising pain therapy ACD440 at NeuPSIG 2025 - PharmaTimes Clinical results from phase 2 study highlight analgesic effects in neuropathic pain patients

#AlzeCure #AlzeCurePharma #pain #paintherapy #ACD440 #NeuPSIG2025 #neuropathicpain #peripheralneuropathicpain #TRPV1antagonist #heatinducedpain #strategicinlicensing #inlicensing #painrelief #painkillers #opioidcrisis #painprecisionmedicine #chronicneuropathicpain
pharmatimes.com/news/alzecur...